文献速递MDS 与骨髓增殖性肿瘤白血病

CC-486(口服阿扎胞苷)延长给药方案治疗髓系恶性肿瘤患者

Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
PubMed 文献 · Am J Hematol · 2018-09-03

这项研究纳入骨髓增生异常综合征、慢性粒单核细胞白血病或急性髓系白血病患者,在药代动力学评估期后,31例患者接受CC-486 300 mg每日一次、每28天周期用药21天。最常见治疗中出现的不良事件为胃肠道(84%)和血液学(81%),MDS/CMML亚组总缓解率为32%,AML亚组为22%。

要点

  • CC-486 300 mg每日一次、每28天周期用药21天,在MDS/CMML亚组总缓解率为32%,AML亚组为22%。
  • 最常见治疗中出现的不良事件为胃肠道(84%的患者)和血液学(81%),3-4级中性粒细胞减少13例(42%)、贫血9例(29%)。
  • 口服CC-486的安全性特征与注射用阿扎胞苷相当,大多数不良事件为血液学和胃肠道事件。

核心结论

  • 口服CC-486的安全性特征与注射用阿扎胞苷相当,大多数不良事件为血液学和胃肠道事件。
  • 延长给药方案(每周期21天)的CC-486在血液系统恶性肿瘤患者中诱导缓解,其中许多患者既往DNMTi治疗失败。

研究设计与样本

  • 研究纳入骨髓增生异常综合征、慢性粒单核细胞白血病或急性髓系白血病患者,在药代动力学评估期后,31例患者(MDS 18例、CMML 4例、AML 9例)进入临床阶段,接受CC-486 300 mg每日一次、每28天周期用药21天。

主要发现

  • 中位年龄71岁(范围53-93),42%的患者年龄≥75岁;AML患者中5例(63%)有既往MDS。
  • CC-486治疗周期中位数为4(范围1-32)。
  • 最常见治疗中出现的不良事件为胃肠道(84%的患者)和血液学(81%);最常见的3-4级治疗中出现的不良事件为中性粒细胞减少(13例,42%)和贫血(9例,29%),10例患者发生4级中性粒细胞减少。
  • 因胃肠道不良事件中断或减量5例(16%),因血液学不良事件中断或减量6例(19%)。
  • MDS/CMML亚组总缓解率(完全缓解、血液学恢复不完全的完全缓解、部分缓解、骨髓完全缓解)为32%,AML亚组(完全缓解/血液学恢复不完全的完全缓解/部分缓解)为22%;MDS/CMML和AML亚组的红细胞输血独立率分别为33%和25%,2例MDS/CMML患者在研究期间最佳反应达到血液学改善。

关键数值与推荐

  • MDS/CMML亚组总缓解率32%,AML亚组总缓解率22%。
  • MDS/CMML亚组红细胞输血独立率33%,AML亚组25%。
  • 3-4级中性粒细胞减少13例(42%),3-4级贫血9例(29%),4级中性粒细胞减少10例。

临床怎么用

  • CC-486允许灵活给药和调整方案以改善耐受性或缓解。
  • 早期治疗周期中的中性粒细胞减少值得关注,可能需要启动预防性抗生素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CC-486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC-486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacokinetic assessment period, 31 patients (MDS n = 18, CMML n = 4, and AML n = 9) entered a clinical phase in which they received CC-486 300 mg once-daily for 21 days of repeated 28-day cycles. Median age was 71 years (range: 53-93); 42% of patients were aged ≥75 years. A total of 5 patients with AML (63%) had prior MDS. Median number of CC-486 treatment cycles was 4 (range: 1-32). The most common treatment-emergent adverse events (TEAEs) were gastrointestinal (84% of patients) and hematologic (81%). Most common grade 3-4 TEAEs were neutropenia (n = 13, 42%) and anemia (n = 9, 29%). Ten patients experienced grade 4 neutropenia. Infrequently, CC-486 dose was interrupted or reduced due to gastrointestinal (n = 5, 16%) or hematologic (n = 6, 19%) TEAEs. Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%. Red blood cell transfusion independence rates in the MDS/CMML and AML subgroups were 33% and 25%, respectively, and 2 MDS/CMML patients attained hematologic improvement as a best response on-study. No baseline gene mutation was predictive of response/nonresponse. CC-486 allows flexible dosing and schedules to improve tolerability or response. Neutropenia in early treatment cycles deserves scrutiny and may warrant initiation of prophylactic antibiotics. KEY POINTS: The safety profile of oral CC-486 was comparable to that of injectable azacitidine; most adverse events were hematological and gastrointestinal. Extended (21-day/cycle) CC-486 dosing induced responses in patients with hematological malignancies, many of whom had prior DNMTi failure.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018. PMID: 30016552. doi:10.1002/ajh.25216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。